• 19 SSO 014 Digital Banners MembershipBanner 1150x135 v5
  • ExpertEd Brand Refresh 1150x135 Surgonc Podcast Banner
  • SSO Mobile App Website Top 1150x135 Banner
  • 19 SSO 014 Digital Banners Landmark Series 1150x135 v5 1

ADVERTISEMENT

Best of SSO

Best of SSO content is selected from the top scoring abstracts that were chosen for presentation at the International Conference on Surgical Cancer Care after intense review and discussion by the SSO Scientific Program Committee.

The following 50 abstracts, from across ten tracks, make up the Best of SSO 2021.

9: Longitudinal Study of Psychosocial Outcomes After Surgery in Women with Unilateral, Sporadic Breast Cancer
12: Factors Associated with Residual Nodal Disease Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (triple-negative) (Alliance)
1: Time to Progression in Elderly Breast Cancer Patients Deemed Non-Surgical Candidates Receiving Primary Endocrine Therapy
2: Sentinel Node Biopsy Should Not be Routine in Older Patients with ER Positive Breast Cancer
4: Effects of Adjuvant Therapy on Recurrence and Survival Among Older Women with Early Stage Breast Cancer
16: High BRCA2 Expression is Associated with Better Survival in Triple Negative Breast Cancer (TNBC)
7: Resource Conservation in Breast Cancer Surgery Care: Important Lessons Learned From the COVID-19 Crisis
25: Short-Course Radiation with Consolidation Chemotherapy Does Not Increase Operative Morbidity Compared to Long-Course Chemoradiation: A Retrospective Study of the U.S. Rectal Cancer Consortium
20: The Ccl20/Ccr6 Axis Promotes Colitis-Associated Carcinogenesis in Smad4 Conditional Knockout Mice
21: Circulating Hybrid Cells as a Novel Liquid Biomarker of Treatment Response in Gastrointestinal Cancers
24: Is there a Role for Adjuvant Chemotherapy in Pathologic Node-Negative, Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation Therapy?
23: Malignant Features in Pre-Treatment Metastatic Lateral Lymph Nodes in Low Rectal Cancers Predict Distant Metastases and Survival, But Not Local Recurrences
33: RNA Sequencing in SBNETs to Identify Novel Therapeutic Targets
28: SOX4 Expression is Associated with Disease Severity in Papillary Thyroid Carcinoma
29: Transcriptome-Driven Analysis of Ligand-Receptor Interactions in the Microenvironment of Pheochromocytoma and Paraganglioma Subtypes
34: Incidence and Predictors of Secondary Cancers in Neuroendocrine Tumors
31: Gastric Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcomes
54: T-Cell Receptor Repertoire Analysis Reveals Positive Correlation Between Intra-tumoral Clonotype Diversity and Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma
47: Novel Treatment Strategy of Targeting Epigenetic Dysregulation in Pancreatic Neuroendocrine Tumors
50: Spatial Computation of the Immune and Stromal Characteristics of Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma
43: Neoadjuvant Chemotherapy-Associated Liver Injury in Pancreatic Cancer: Incidence and Implications
45: The Impact of Medicaid Expansion on Pancreatic Cancer Survival
37: Patterns of Whole Genome Sequencing and Actionable Mutations in Resected Cholangiocarcinoma
56: A Novel C-terminal Hsp90 Inhibitor KU758 Synergizes with MEK and BRAF Inhibitors in Melanoma
60: Prognostic Implications of Tumor-Positive Sentinel Lymph Node Drainage to Multiple Versus Single Basins in Melanoma
57: Differences in Myeloid Derived Suppressor Cell Populations in Patients with Ulcerated vs Nonulcerated Melanoma Receiving Immune Checkpoint Blockade
63: A Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma
55: Is the Presence of Tumor Infiltrating Lymphocytes Prognostic in Melanoma Patients?
36: Identification of SYCP2 as a Candidate Epigenetically-Regulated Driver of HPV16-Positive Head and Neck Cancers
35: A Change in Surgical Margin: Do Wider Surgical Margins Lead to Decreased Rates of Local Recurrence in T1 and T2 Oral Tongue Cancer?
 
70: Application of Immune-Enhanced Tumor Organoids in Establishing Immunotherapy Efficacy in Appendiceal Cancer
67: Goblet Cell Origins of Human Appendiceal Mucinous Neoplasms and Pseudomyxoma Peritonei Tumors
71: Effect of Colorectal Cancer Gene Mutations on Mitomycin Dose and Heat-Induced Augmentation of Cytotoxicity
68: Cytoplasmic Expression of XPO7 Distinguishes a Subset of Ovarian Carcinoma Vulnerable to SLK Inhibition
69: Expression of PD-L1 in Malignant Peritoneal Mesothelioma (MPM)
77: Quality of the Surgical Episode Mediates a Large Proportion of Socioeconomic-Based Survival Disparities in Patients with Resected Stage I-III Colon Cancer
76: Association of Medicaid Eligibility with Outcomes and Spending for Medicare Beneficiaries Among High Quality Hospitals for Cancer Surgery
78: Is Textbook Oncologic Outcome a Valid Hospital Quality Metric Following High-risk Surgical Oncology Procedures?
74: Patient-Reported Symptom Burden After Cancer Surgery in Older Adults: A Population-Level Analysis
81: Impact of ERAS® on Opioid Prescribing Practices After Breast Surgery
86: Extracellular Vesicle MDM2 DNA: A Biomarker for Retroperitoneal Liposarcoma?
85: Sarcomas with Low Cancer-associated Fibroblasts (CAF) Associated with Worse Survival
90: Oncological Outcomes After Major Vascular Resections for Primary Retroperitoneal Liposarcoma
88: Multi-Institution Validation of Prognostic Nomograms for Outcomes After Resection of Primary Retroperitoneal Sarcoma
83: Should Imaging Surveillance be Used in Cutaneous Leiomyosarcoma?
94: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Following Neoadjuvant Chemoradiation Therapy: First Results of the CheckMate 577 Study
92: Combination Therapy with Imipridones and MEK Inhibitors Demonstrate Synergy in Gastric Adenocarcinoma Cell Lines
95: Medicaid Expansion Is Associated with Earlier Diagnosis of Gastric Cancer
96: Local Endoscopic Resection is Inferior to Gastrectomy for Early Clinical Stage T1a and T1b Gastric Adenocarcinoma: A Propensity-Matched Study
97: Determinants of Survival for Neoadjuvant-Treated Node-Negative Gastric Cancer
Navigate
Scroll to Top